GO:0060340 positive regulation of type I interferon-mediated signaling pathway: Antiviral Immunity Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060340 describes any process that increases the rate, frequency or extent of type I interferon-mediated signaling, the central antiviral innate immune circuit.
• Positive regulation can be achieved by removing negative regulators such as SOCS3 or DCST1, or by activating kinases such as NDR1 that amplify interferon-stimulated gene (ISG) transcription.
• Viral pathogens frequently suppress this positive regulation to evade immunity, as shown for murine gammaherpesvirus 68 M2 protein and enterovirus-mediated miR-526a downregulation.
• MicroRNAs such as miR-122 and miR-526a act as upstream rheostats that tune the strength of type I interferon signaling.
• Dysregulated positive regulation of type I interferon signaling is linked to viral persistence, oral squamous cell carcinoma biology and HPV infection.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the primary tools for causally testing candidate regulators of GO:0060340.
Description
Type I interferons (IFN-alpha/beta) are the first line of antiviral defense, and their signaling must be tightly amplified to clear pathogens without causing immunopathology. GO:0060340, positive regulation of type I interferon-mediated signaling pathway, captures every process that increases the rate, frequency or extent of this pathway. Researchers study this term because it defines the host factors and viral countermeasures that determine whether an infection is controlled or becomes chronic. The pathway is also a therapeutic target: enhancing it can suppress hepatitis B virus, whereas inappropriate activation contributes to inflammatory disease. Understanding which genes positively regulate type I interferon signaling therefore has direct implications for antiviral drug design, vaccine adjuvant development and cancer immunotherapy.
positive regulation of type I interferon-mediated signaling pathway At A Glance
| GO ID | GO:0060340 |
|---|---|
| GO term | positive regulation of type I interferon-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | positive regulation of type I interferon-mediated signalling pathway |
| Definition | Any process that increases the rate, frequency or extent of a type I interferon-mediated signaling pathway. |
| Major function | Amplification of IFN-alpha/beta signal transduction and ISG expression during antiviral innate immunity. |
| Key negative regulators removed | SOCS3, DCST1 |
| Key positive kinases | NDR1, GSK3 |
| Viral evasion examples | MHV-68 M2 protein, enterovirus miR-526a downregulation |
What Is GO:0060340?
GO:0060340 is a biological process term meaning any molecular event that increases the rate, frequency or extent of type I interferon-mediated signaling. In practice, this includes transcriptional upregulation of interferon-stimulated genes (ISGs), stabilization of signaling intermediates, removal of negative regulators such as SOCS3 or DCST1, and kinase cascades that potentiate STAT activation. It is the positive counterpart to negative regulation of the same pathway and is essential for effective antiviral immunity.
Why Is positive regulation of type I interferon-mediated signaling pathway Important in Cell Biology?
Positive regulation of type I interferon signaling determines the outcome of viral infection, the efficacy of interferon-based therapies and the balance between immunity and autoinflammation. Loss of positive regulators causes viral susceptibility, while excessive activation drives interferonopathies. Because many viruses encode proteins that block this positive regulation, the term is a focal point for understanding host-pathogen conflict and for developing host-directed antivirals.
• Controls clearance of hepatitis B virus by enhancing interferon-mediated suppression.
• Defines host factors such as NDR1 that positively regulate antiviral innate immunity.
• Identifies negative regulators like DCST1 whose removal boosts type I interferon signaling.
• Explains viral immune evasion by MHV-68 M2 protein and enterovirus miR-526a downregulation.
• Links microRNA networks (miR-122, miR-526a) to interferon pathway strength.
• Relevant to oral squamous cell carcinoma biology through apolipoprotein D dysregulation.
• Provides mechanistic context for HPV16 tissue-specific gene expression and immune control.
• Guides CRISPR screens for positive regulators of ISG induction.
• Supports development of interferon adjuvants and host-directed antivirals.
• Helps interpret interferonopathies and chronic viral persistence.
What Happens During positive regulation of type I interferon-mediated signaling pathway?
Upstream sensing and interferon induction
In simple terms: The cell first detects viral RNA or DNA and turns on interferon genes.
Positive regulation begins with pattern recognition receptors that trigger type I interferon production; enterovirus infection downregulates miR-526a, which normally restrains RIG-I-dependent innate immune response, thereby altering the positive regulation of interferon signaling. This step sets the ceiling for subsequent ISG amplification.
Removal of negative regulators (SOCS3, DCST1)
In simple terms: Taking the brakes off the interferon pathway makes the signal stronger.
miR-122 downregulates SOCS3, a negative regulator, and thereby enhances interferon-mediated suppression of hepatitis B virus, a clear example of positive regulation. Global ubiquitome profiling identified the E3 ubiquitin ligase DCST1 as a novel negative regulator of type I interferon signaling, so its inhibition or knockout increases pathway activity.
Kinase cascades that amplify STAT activation
In simple terms: Kinases act as accelerators that keep the interferon signal running.
Hippo kinase NDR1 crosstalks with GSK3 and positively regulates type I interferon-mediated antiviral innate immunity, demonstrating that kinase networks can directly increase the rate and extent of the pathway. This amplification step is required for robust ISG transcription.
Viral interference with positive regulation
In simple terms: Viruses try to cut the accelerator wire to survive.
Murine gammaherpesvirus 68 latency-associated M2 protein inhibits interferon-mediated antiviral activity, effectively blocking positive regulation. Similarly, enterovirus-mediated downregulation of miR-526a dampens RIG-I-dependent innate immune response, reducing type I interferon signaling. These examples define the term by showing what happens when positive regulation is lost.
Tissue-specific and disease context
In simple terms: The same pathway behaves differently in different tissues and tumors.
Tissue-specific gene expression during productive human papillomavirus 16 infection of cervical, foreskin and tonsil epithelium shows that interferon-related positive regulation is context-dependent. In oral squamous cell carcinoma, apolipoprotein D downregulation has been validated across databases and may intersect with interferon signaling.
Key Genes Involved in GO:0060340 positive regulation of type I interferon-mediated signaling pathway
The following genes and proteins have been experimentally linked to positive regulation of type I interferon-mediated signaling in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SOCS3 | Negative regulator whose downregulation enhances interferon signaling | Target for miR-122-based enhancement of HBV suppression |
| miR-122 | Downregulates SOCS3 to boost interferon-mediated HBV suppression | Upstream rheostat of positive regulation |
| DCST1 | E3 ubiquitin ligase acting as negative regulator of type I interferon signaling | Knockout candidate to increase pathway activity |
| NDR1 | Hippo kinase that positively regulates antiviral innate immunity | Kinase target for amplifying interferon signaling |
| GSK3 | Crosstalks with NDR1 in positive regulation | Co-target in kinase amplification studies |
| M2 (MHV-68) | Viral protein inhibiting interferon-mediated antiviral activity | Model of viral evasion of positive regulation |
| miR-526a | Downregulated by enterovirus; normally restrains RIG-I-dependent response | MicroRNA node controlling positive regulation |
| RIG-I | Pattern recognition receptor in the interferon induction arm | Upstream sensor affected by miR-526a loss |
| Apolipoprotein D | Downregulated in OSCC; multi-database validated | Potential interferon-related biomarker in OSCC |
| HPV16 E6/E7 | Viral oncoproteins expressed tissue-specifically during infection | Context for interferon pathway modulation |
| STAT1 | Canonical transcription factor downstream of type I interferon | Readout of pathway activation |
| STAT2 | Canonical transcription factor downstream of type I interferon | Readout of pathway activation |
| IRF9 | Component of ISGF3 complex mediating ISG transcription | Readout of pathway activation |
| ISG15 | Interferon-stimulated gene product | Marker of positive regulation |
| OAS1 | Interferon-stimulated antiviral effector | Marker of positive regulation |
| MX1 | Interferon-stimulated antiviral effector | Marker of positive regulation |
| IFIT1 | Interferon-stimulated antiviral effector | Marker of positive regulation |
| PKR (EIF2AK2) | Interferon-stimulated antiviral kinase | Marker of positive regulation |
How Is positive regulation of type I interferon-mediated signaling pathway Regulated?
Positive regulation of type I interferon signaling is itself regulated at multiple levels. MicroRNAs such as miR-122 and miR-526a tune the abundance of negative regulators and sensors, thereby setting pathway sensitivity. Ubiquitination by E3 ligases such as DCST1 provides a degradative checkpoint that limits signaling, so removal of DCST1 increases pathway output. Kinase networks involving NDR1 and GSK3 provide phosphorylation-dependent amplification. Viral proteins such as MHV-68 M2 can override these positive inputs to establish latency. Together, these layers determine the rate and extent of type I interferon-mediated signaling in a cell-type-specific manner.
positive regulation of type I interferon-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SOCS3 | Hepatitis B virus infection | Knockout hepatoma cells with miR-122 mimic |
| DCST1 | Type I interferon signaling regulation | Knockout HEK293T or THP-1 cells |
| NDR1 | Antiviral innate immunity | Kinase-dead point mutation knock-in |
| M2 (MHV-68) | Herpesvirus immune evasion | Overexpression in interferon reporter cells |
| miR-526a | Enterovirus immune evasion | Knockout or sponge in RIG-I reporter cells |
Chronic hepatitis B virus infection
Downregulation of SOCS3 by miR-122 enhances interferon-mediated suppression of hepatitis B virus, showing that boosting positive regulation of type I interferon signaling can improve viral control. This provides a rationale for host-directed therapies that remove negative regulators.
Herpesvirus and enterovirus immune evasion
Murine gammaherpesvirus 68 M2 protein inhibits interferon-mediated antiviral activity, and enterovirus downregulates miR-526a to dampen RIG-I-dependent innate immune response. Both examples illustrate how viruses target positive regulation to persist.
Oral squamous cell carcinoma
Apolipoprotein D downregulation in OSCC has been validated across multiple databases and carries clinical significance, suggesting that interferon-related positive regulation may be relevant to tumor immune biology. Further work is needed to causally link this gene to GO:0060340.
Human papillomavirus infection
Tissue-specific gene expression during productive HPV16 infection of cervical, foreskin and tonsil epithelium indicates that interferon pathway modulation is context-dependent. This has implications for understanding how HPV evades innate immunity in different anatomical sites.
From positive regulation of type I interferon-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DCST1 increase type I interferon signaling? | DCST1 knockout cell line |
| Is NDR1 kinase activity required for positive regulation? | NDR1 kinase-dead point mutation knock-in |
| Does miR-122-mediated SOCS3 downregulation enhance HBV suppression? | SOCS3 3'UTR knock-in with miR-122 site mutation |
| Can viral M2 protein block positive regulation? | M2 overexpression in ISG reporter cells |
| Does miR-526a loss affect RIG-I-dependent response? | miR-526a knockout or overexpression |
| Is apolipoprotein D causally linked to interferon signaling in OSCC? | Apolipoprotein D knockout in OSCC lines |
How to Study the positive regulation of type I interferon-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Genes required for ISG induction | Identify positive regulators of GO:0060340 |
| Phosphoproteomics | Phosphorylation of STAT1/STAT2 and kinases | Quantify pathway amplification |
| 3'UTR luciferase reporter | MicroRNA-mediated regulation of SOCS3 or RIG-I | Validate miR-122 and miR-526a mechanisms |
| RNA-seq of ISGs | ISG15, OAS1, MX1, IFIT1 expression | Measure positive regulation output |
| Viral infection assay | Viral replication under interferon treatment | Test host-directed enhancement |
| Immunoblotting | SOCS3, DCST1, NDR1 protein levels | Confirm knockout or overexpression |
| Reporter cell line (ISRE-luciferase) | Interferon-stimulated response element activity | High-throughput screening |
| Tissue-specific expression profiling | Gene expression during HPV16 infection | Context-dependent pathway analysis |
CRISPR knockout screens for positive regulators
Genome-wide knockout screens can identify genes whose loss reduces ISG induction, directly mapping positive regulators of GO:0060340. DCST1 was identified through global functional profiling of the human ubiquitome as a negative regulator, illustrating how knockout screens reveal pathway modulators.
Phosphoproteomics and kinase assays
Because NDR1 and GSK3 act through phosphorylation, phosphoproteomics and in vitro kinase assays are used to measure changes in STAT activation and downstream ISG expression. These methods quantify the rate and extent of pathway activation.
MicroRNA and 3'UTR reporter assays
Luciferase reporters containing the SOCS3 3'UTR are used to test miR-122-mediated downregulation, a direct mechanism of positive regulation. Similar reporters validate miR-526a targeting in the RIG-I pathway.
Viral infection and ISG expression profiling
Infection with MHV-68, enterovirus or HPV16 followed by RNA-seq of ISGs such as ISG15, OAS1, MX1 and IFIT1 measures pathway output in relevant tissue contexts. Tissue-specific expression profiling during HPV16 infection highlights context-dependent effects.
How CRISPR Can Be Used to Study GO:0060340 positive regulation of type I interferon-mediated signaling pathway
Knockout
CRISPR knockout of negative regulators such as DCST1 or SOCS3 is used to test whether removing a brake increases type I interferon signaling, directly assaying GO:0060340. Knockout of positive regulators like NDR1 would be expected to reduce pathway output.
Point Mutation
Point mutation knock-in of kinase-dead NDR1 or GSK3 mutants allows separation of catalytic activity from scaffolding function in positive regulation. Similarly, mutation of the miR-122 binding site in the SOCS3 3'UTR tests microRNA-mediated regulation.
Knock-in
Knock-in of tagged STAT1, STAT2 or IRF9 enables chromatin immunoprecipitation and imaging of the ISGF3 complex during positive regulation. Tagged knock-in of viral sensors can also reveal pathway dynamics.
Overexpression
Overexpression of viral proteins such as MHV-68 M2 or of host kinases such as NDR1 is used to test sufficiency for inhibiting or enhancing type I interferon signaling. Overexpression of miR-526a or miR-122 validates microRNA-mediated positive regulation.
How EDITGENE Supports positive regulation of type I interferon-mediated signaling pathway Research
Researchers studying positive regulation of type I interferon-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in amplifying or restraining antiviral immunity. EDITGENE provides the full suite of CRISPR cell model services to move from correlation to causation in this pathway.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of type I interferon-mediated signaling pathway research.
Frequently Asked Questions About positive regulation of type I interferon-mediated signaling pathway
What is GO:0060340?
GO:0060340 is the Gene Ontology term for positive regulation of type I interferon-mediated signaling pathway, meaning any process that increases the rate, frequency or extent of type I interferon signaling.
What genes are involved in positive regulation of type I interferon-mediated signaling pathway?
Key genes include SOCS3, DCST1, NDR1, GSK3, miR-122, miR-526a and RIG-I, as shown in antiviral and functional profiling studies.
How do viruses evade type I interferon signaling?
Viruses such as murine gammaherpesvirus 68 use the M2 protein to inhibit interferon-mediated antiviral activity, and enterovirus downregulates miR-526a to dampen RIG-I-dependent innate immune response.
What is the role of SOCS3 in interferon signaling?
SOCS3 is a negative regulator; its downregulation by miR-122 enhances interferon-mediated suppression of hepatitis B virus, effectively increasing positive regulation.
What is DCST1?
DCST1 is an E3 ubiquitin ligase identified as a novel negative regulator of type I interferon signaling through global functional profiling of the human ubiquitome.
How does NDR1 regulate antiviral immunity?
Hippo kinase NDR1 crosstalks with GSK3 and positively regulates type I interferon-mediated antiviral innate immunity.
What is miR-526a?
miR-526a is a microRNA downregulated by enterovirus that normally restrains RIG-I-dependent innate immune response; its loss reduces type I interferon signaling.
Is positive regulation of type I interferon signaling relevant to cancer?
Apolipoprotein D downregulation in oral squamous cell carcinoma has been validated across databases and may intersect with interferon-related biology.
How can I study positive regulation of type I interferon signaling?
CRISPR knockout screens, phosphoproteomics, 3'UTR reporters, RNA-seq of ISGs and viral infection assays are standard methods.
What models are used for GO:0060340 research?
Knockout, point-mutation, knock-in and overexpression cell models, as well as CRISPR library screens, are used to test causal roles of pathway regulators.
Conclusion
GO:0060340, positive regulation of type I interferon-mediated signaling pathway, is a central node in antiviral immunity that integrates microRNA regulation, ubiquitination checkpoints and kinase amplification. The cited literature shows that removing negative regulators such as SOCS3 and DCST1, or activating kinases such as NDR1, increases pathway output, while viral proteins like MHV-68 M2 and enterovirus-driven miR-526a loss suppress it. These findings have direct implications for hepatitis B, herpesvirus and enterovirus infections, as well as for HPV16 and oral squamous cell carcinoma biology. CRISPR-based cell models remain the most rigorous way to establish causality for candidate regulators of this pathway.
References
- 1. Gao D et al.. 2015. Down-regulation of suppressor of cytokine signaling 3 by miR-122 enhances interferon-mediated suppression of hepatitis B virus.. Antiviral Res 118:20-8 PMID: 25766860
- 2. Nair S et al.. 2016. Global functional profiling of human ubiquitome identifies E3 ubiquitin ligase DCST1 as a novel negative regulator of Type-I interferon signaling.. Sci Rep 6:36179 PMID: 27782195
- 3. Shi T et al.. 2026. Hippo kinase NDR1 crosstalks with GSK3 and positively regulates type I interferon-mediated antiviral innate immunity.. Mol Immunol 192:13-20 PMID: 41762937
- 4. Liang X et al.. 2004. Inhibition of interferon-mediated antiviral activity by murine gammaherpesvirus 68 latency-associated M2 protein.. J Virol 78(22):12416-27 PMID: 15507628
- 5. Xu C et al.. 2014. Downregulation of microRNA miR-526a by enterovirus inhibits RIG-I-dependent innate immune response.. J Virol 88(19):11356-68 PMID: 25056901
- 6. Wang S et al.. 2026. Apolipoprotein D downregulation in OSCC: multi-database validation and clinical significance.. BMC Med Genomics 19(1) PMID: 41808079
- 7. Chatterjee S et al.. 2019. Tissue-Specific Gene Expression during Productive Human Papillomavirus 16 Infection of Cervical, Foreskin, and Tonsil Epithelium.. J Virol 93(17) PMID: 31189705
